Goldman doesn't see "significant downside" to shares of Merck (MRK +0.5%), but notes that...

|About: Merck & Co Inc. (MRK)|By:, SA News Editor

Goldman doesn't see "significant downside" to shares of Merck (MRK +0.5%), but notes that today's news (previous) marks "another pipeline setback in a year that has seen a tredaptive failure [and an] odanacatib delay." Analyst Jami Rubin has now pushed his suvorexant "launch assumption from 2014 out to 2015."